Template:Congestive heart failure: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(37 intermediate revisions by 8 users not shown)
Line 1: Line 1:
{| class="infobox bordered" style="width: 15em; text-align: left; font-size: 90%; background:AliceBlue"
{| class="infobox bordered" style="width:15%; text-align:left; font-size:90%; background:AliceBlue"
 
|-
|-
| colspan="1" style="text-align:center; background:DarkGray" |
| colspan="1" style="text-align:center; background:DarkGray" |'''Congestive Heart Failure Microchapters'''


'''Congestive heart failure Microchapters
'''
|- bgcolor="LightGrey"
|- bgcolor="LightGrey"
!
!
Line 23: Line 22:
!
!
[[Congestive heart failure overview|Overview]]
[[Congestive heart failure overview|Overview]]
|-
!
|- bgcolor="Pink"
!
[[Congestive heart failure historical perspective|Historical Perspective]]
|-  
|-  
!
!
Line 34: Line 39:
|- bgcolor="Pink"
|- bgcolor="Pink"
!
!
[[Congestive heart failure pathophysiology|Pathophysiology]]
Pathophysiology
:[[Congestive heart failure pathophysiology#Systolic dysfunction|Systolic Dysfunction]]
:[[Diastolic dysfunction pathophysiology|Diastolic Dysfunction]]
:[[Congestive heart failure with preserved EF|HFpEF]]
:[[Congestive heart failure with reduced EF|HFrEF]]
|-  
|-  
!
!
Line 43: Line 52:
|-  
|-  
!
!
|- bgcolor="Pink"
|- bgcolor="Pink"
!
!
Line 48: Line 58:
|-  
|-  
!
!
|- bgcolor="Pink"
|- bgcolor="Pink"
!
!
Line 57: Line 68:
!
!
[[Congestive heart failure risk factors|Risk Factors]]
[[Congestive heart failure risk factors|Risk Factors]]
|-
!
|- bgcolor="Pink"
!
[[Congestive heart failure Screening|Screening]]
|-  
|-  
!
!
Line 107: Line 124:
|-  
|-  
!
!
|- bgcolor="LightSkyBlue"
|- bgcolor="LightSkyBlue"
!
!
Line 112: Line 130:
|-  
|-  
!
!
|- bgcolor="LightSkyBlue"
|- bgcolor="LightSkyBlue"
!
!
Line 138: Line 157:
|- bgcolor="LightSkyBlue"
|- bgcolor="LightSkyBlue"
!
!
[[Congestive heart failure endomyocardial biopsy|Endomyocardial biopsy]]
[[Congestive heart failure Other Imaging Studies|Other Imaging Studies]]
|-
!
 
|- bgcolor="LightSkyBlue"
!
[[Congestive heart failure other diagnostic studies|Other Diagnostic Studies]]
|-  
|-  
!
!
Line 157: Line 182:
!
!
Medical Therapy:
Medical Therapy:
|- bgcolor="PaleTurquoise"
!
: [[Congestive heart failure pharmacotherapy|Summary]]
|- bgcolor="PaleTurquoise"
!
: [[Congestive heart failure acute pharmacotherapy|Acute Pharmacotherapy]]
: [[Congestive heart failure acute pharmacotherapy|Acute Pharmacotherapy]]
: [[Chronic Pharmacotherapy]]:
|- bgcolor="PaleTurquoise"
!
: [[Congestive heart failure with preserved EF pharmacotherapy|Chronic Pharmacotherapy in HFpEF]]
|- bgcolor="PaleTurquoise"
!
: [[Congestive heart failure chronic pharmacotherapy|Chronic Pharmacotherapy in HFrEF]]
:: [[Congestive heart failure diuretics|Diuretics]]
:: [[Congestive heart failure diuretics|Diuretics]]
:: [[Congestive heart failure ACE inhibitors|ACE Inhibitors]]
:: [[Congestive heart failure ACE inhibitors|ACE Inhibitors]]
Line 169: Line 204:
:: [[Congestive heart failure positive inotropics|Positive Inotropics]]
:: [[Congestive heart failure positive inotropics|Positive Inotropics]]
:: [[Congestive heart failure anticoagulants|Anticoagulants]]
:: [[Congestive heart failure anticoagulants|Anticoagulants]]
:: [[Congestive heart failure angiotensin receptor-neprilysin inhibitor|Angiotensin Receptor-Neprilysin Inhibitor]]
:: [[Congestive heart failure antiarrhythmic Drugs|Antiarrhythmic Drugs]]
:: [[Congestive heart failure antiarrhythmic Drugs|Antiarrhythmic Drugs]]
:: [[Congestive heart failure other pharmacotherapies#Nutritional Supplements|Nutritional Supplements]]
:: [[Congestive heart failure other pharmacotherapies#Nutritional Supplements|Nutritional Supplements]]
::[[Congestive heart failure omega-3-fatty acid|Omega-3-Fatty Acid]]
:: [[Congestive heart failure other pharmacotherapies#Hormonal Therapies|Hormonal Therapies]]
:: [[Congestive heart failure other pharmacotherapies#Hormonal Therapies|Hormonal Therapies]]
:[[Congestive heart failure drugs to avoid|Drugs to Avoid]]
:[[Congestive heart failure drugs to avoid|Drugs to Avoid]]
Line 200: Line 235:
|- bgcolor="PaleTurquoise"
|- bgcolor="PaleTurquoise"
!
!
2013 ACCF/AHA Guideline for the Management of Heart Failure
ACC/AHA Guideline Recommendations
: [[2013 ACCF/AHA Guideline Definition of HF|Definitions of HFrEF and HFpEF]
: [[Congestive heart failure AHA recommendations|Initial and Serial Evaluation of the HF Patient]]
: [[2013 ACCF/AHA Guideline Initial and Serial Evaluation of the HF Patient|Evaluation of the HF]]
: [[Congestive heart failure AHA recommendations for hospitalized patient|Hospitalized Patient]]
: [[2013 ACCF/AHA Guideline Treatment of Stages A to D|Stage A]]
: [[2013 ACCF/AHA Guideline Treatment of Stages A to D|Stage B]]
: [[2013 ACCF/AHA Guideline Treatment of Stages A to D|Stage C]]
: [[2013 ACCF/AHA Guideline Treatment of Stages A to D|Stage D]]
: [[2013 ACCF/AHA Guideline The Hospitalized Patient|Hospitalized Patient]]
: [[2013 ACCF/AHA Guideline Surgical/Percutaneous/Transcather Interventional Treatments of HF]]
 
|- bgcolor="PaleTurquoise"
!
2009 ACC/AHA Guideline Recommendations:
 
: [[Congestive heart failure AHA recommendations for hospitalized patient|Hospitalized Patients]]
: [[Congestive heart failure AHA recommendations for patients with a prior MI|Patients With a Prior MI]]
: [[Congestive heart failure AHA recommendations for patients with a prior MI|Patients With a Prior MI]]
: [[Congestive heart failure sudden cardiac death prevention|Sudden Cardiac Death Prevention]]
: [[Congestive heart failure sudden cardiac death prevention|Sudden Cardiac Death Prevention]]
: [[Congestive heart failure AHA recommendations Surgical/Percutaneous/Transcather Interventional Treatments of HF|Surgical/Percutaneous/Transcather Interventional Treatments of HF]]
: [[Congestive heart failure treatment of patients at high risk for developing heart failure (Stage A)|Patients at high risk for developing heart failure (Stage A)]]
: [[Congestive heart failure treatment of patients at high risk for developing heart failure (Stage A)|Patients at high risk for developing heart failure (Stage A)]]
: [[Congestive heart failure treatment of patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)|Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)]]
: [[Congestive heart failure treatment of patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)|Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)]]
: [[Congestive heart failure treatment of patients with current or prior symptoms of heart failure (Stage C)|Patients with current or prior symptoms of heart failure (Stage C)]]
: [[Congestive heart failure treatment of patients with current or prior symptoms of heart failure (Stage C)|Patients with current or prior symptoms of heart failure (Stage C)]]
: [[Congestive heart failure treatment of patients with refractory end-stage heart failure (Stage D)|Patients with refractory end-stage heart failure (Stage D)]]
: [[Congestive heart failure treatment of patients with refractory end-stage heart failure (Stage D)|Patients with refractory end-stage heart failure (Stage D)]]
: [[Congestive heart failure AHA recommendations Coordinating Care for Patients With Chronic HF|Coordinating Care for Patients With Chronic HF]]
: [[Congestive heart failure AHA recommendations Quality Metrics/Performance Measures|Quality Metrics/Performance Measures]]
|-  
|-  
!
!
Line 242: Line 268:
: [[Congestive heart failure treatment of patients who have concomitant disorders|Patients who have concomitant disorders]]
: [[Congestive heart failure treatment of patients who have concomitant disorders|Patients who have concomitant disorders]]
: [[Congestive heart failure and obstructive sleep apnea|Obstructive Sleep Apnea in the Patient with CHF]]
: [[Congestive heart failure and obstructive sleep apnea|Obstructive Sleep Apnea in the Patient with CHF]]
: [[Unstable angina / non ST elevation myocardial infarction Heart Failure and Cardiogenic Shock|NSTEMI with Heart Failure and Cardiogenic Shock]]
|-  
|-  
!
!
Line 325: Line 352:
|- bgcolor="LightYellow"
|- bgcolor="LightYellow"
!
!
[http://blogsearch.google.com/blogsearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wb Blogs on {{PAGENAME}}]</small>
[http://blogsearch.google.com/blogsearch?q={{urlencode:{{#if:{{{1|}}}|{{{1}}}|{{PAGENAME}}}}}}&ie=UTF-8&oe=utf-8&rls=org.mozilla:en-US:official&client=firefox-a&um=1&sa=N&tab=wb Blogs on {{PAGENAME}}]
|-  
|-  
!  
!  
Line 341: Line 368:
!  
!  


|-
|}
|}

Latest revision as of 17:06, 23 December 2019

Congestive Heart Failure Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Systolic Dysfunction
Diastolic Dysfunction
HFpEF
HFrEF

Causes

Differentiating Congestive heart failure from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Clinical Assessment

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Cardiac MRI

Echocardiography

Exercise Stress Test

Myocardial Viability Studies

Cardiac Catheterization

Other Imaging Studies

Other Diagnostic Studies

Treatment

Invasive Hemodynamic Monitoring

Medical Therapy:

Summary
Acute Pharmacotherapy
Chronic Pharmacotherapy in HFpEF
Chronic Pharmacotherapy in HFrEF
Diuretics
ACE Inhibitors
Angiotensin receptor blockers
Aldosterone Antagonists
Beta Blockers
Ca Channel Blockers
Nitrates
Hydralazine
Positive Inotropics
Anticoagulants
Angiotensin Receptor-Neprilysin Inhibitor
Antiarrhythmic Drugs
Nutritional Supplements
Hormonal Therapies
Drugs to Avoid
Drug Interactions
Treatment of underlying causes
Associated conditions

Exercise Training

Surgical Therapy:

Biventricular Pacing or Cardiac Resynchronization Therapy (CRT)
Implantation of Intracardiac Defibrillator
Ultrafiltration
Cardiac Surgery
Left Ventricular Assist Devices (LVADs)
Cardiac Transplantation

ACC/AHA Guideline Recommendations

Initial and Serial Evaluation of the HF Patient
Hospitalized Patient
Patients With a Prior MI
Sudden Cardiac Death Prevention
Surgical/Percutaneous/Transcather Interventional Treatments of HF
Patients at high risk for developing heart failure (Stage A)
Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)
Patients with current or prior symptoms of heart failure (Stage C)
Patients with refractory end-stage heart failure (Stage D)
Coordinating Care for Patients With Chronic HF
Quality Metrics/Performance Measures

Implementation of Practice Guidelines

Congestive heart failure end-of-life considerations

Specific Groups:

Special Populations
Patients who have concomitant disorders
Obstructive Sleep Apnea in the Patient with CHF
NSTEMI with Heart Failure and Cardiogenic Shock

Congestive heart failure On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Congestive heart failure

CDC on Congestive heart failure

Congestive heart failure in the news

Blogs on Congestive heart failure

Directions to Hospitals Treating Congestive heart failure

Risk calculators and risk factors for Congestive heart failure

Retrieved from "https://www.wikidoc.org/index.php?title=Template:Congestive_heart_failure&oldid=1592800"